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RUNNING HEAD : MANDIBULAR OSTEOSARCOMA WITH MDM2/RASAL1 
AMPLIFICATION 
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ABSTRACT  
In contrast to long bone osteosarcoma, mandibular osteosarcoma are highly heterogeneous 
and morphologically overlap with benign tumors, obscuring diagnosis and treatment 
selection. Molecular characterization is difficult due to the paucity of available specimens of 
this rare disease. We aimed to characterize the spectrum of mandibular osteosarcoma using 
immunohistochemistry and molecular techniques (quantitative polymerase chain reaction,  
sequencing) and compare them with benign fibro-osseous lesions. Forty-nine paraffin-
embedded mandible osteosarcoma tissue samples were collected retrospectively and 
compared with 10 fibrous dysplasia and 15 ossifying fibroma cases. These were analyzed for 
molecular markers thought to differ between the different diseases and subtypes: MDM2 
(murine double-minute type-2) overexpression; GNAS (guanine nucleotide-binding 
protein/alpha subunit) mutations; and amplification of MDM2 and/or RASAL1 (RAS protein 
activator like-1). Five fibroblastic high-grade osteosarcoma subtypes showed MDM2
amplification, including two with a microscopic appearance of high-grade osteosarcoma with 
part low-grade osteosarcoma (differentiated/dedifferentiated osteosarcoma) and MDM2 
overexpression. The other three contained a co-amplification of MDM2 and RASAL1, a
signature also described for juvenile ossifying fibroma, with no overexpression of MDM2. 
These were of the giant cell-rich high-grade osteosarcoma, with areas mimicking juvenile 
ossifying fibroma (ossifying-fibroma-like osteosarcoma). Our results show that some 
diagnosed high-grade osteosarcoma are differentiated/dedifferentiated osteosarcomas and 
harbor an overexpression and amplification of MDM2. In addition, juvenile ossifying 
fibromas can potentially evolve into giant cell-rich high-grade osteosarcomas and are 
characterized by a RASAL1 amplification (osteosarcoma with juvenile ossifying fibroma-like 
genotype). Thus, the presence of a RASAL1 amplification in ossifying fibroma may indicate a
requirement for closer follow-up and more aggressive management.  
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NON-STANDARD ABBREVIATIONS 
GFPO: Groupe Français de Pathologistes Osseux,  
RESOS: Réseau de référence en sarcomes osseux 
GSF-GETO: Groupe Sarcome Français – Groupe d’Etude des Tumeurs Osseuses  
REFCOR: Réseau d’Expertise Français des Cancers ORL Rares  
RCN: Rare Cancer Network 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
7 
 
1.1 INTRODUCTION 
Mandibular osteosarcoma (MOS) account for less than 10% of all osteosarcoma (OS) 
[1] and, in contrast to their non-head and neck counterparts, they are characterized by a later 
onset and a lower propensity for distant metastases. Most series of MOS cases are of limited 
statistical value for the molecular characterization of different mandibular subtypes due to 
their rarity and histological heterogeneity. Some maxillary OS have been linked with the 
overexpression and amplification of MDM2 (murine double-minute type 2) and CDK4 
(cyclin-dependent kinase 4), and the overexpression of Ezrin (a membrane-cytoskeleton linker 
protein involved in metastases), but these are the only molecular characterization studies 
reported thus far and have provided no prognostic value [2–4].
According to the WHO 2013 classification [5], low-grade OS (LGOS) represent 5-7% 
of all OS and are characterized by a paucicellular stroma with fusiform cells exhibiting minor 
cytonuclear atypia and well-differentiated bone trabeculae. Their genomic profile includes the 
presence of episomal ring neochromosomes containing a high-level amplification of the 
12q13-15 region harboring the MDM2 and CDK4 genes. In 10-36% of LGOS cases some 
dedifferentiation into high-grade OS (HGOS) can occur, such that areas of low- and high-
grade tumor can coexist microscopically (defined here as HGOS with part LGOS, or 
differentiated/dedifferentiated OS). Compared to the LGOS part, the HGOS contingent is 
composed of cells with larger atypia and a more immature neoplastic osteoid production [5].
Tumour necrosis may also be present. Amplification of the MDM2 and CDK4 genes is also 
preserved in the dedifferentiated form of OS and is not observed in benign fibro-osseous
lesions, providing an important diagnostic tool and prognostic factor [6]. When the LGOS in
biopsy or surgical resection specimens, the diagnosis of dedifferentiated OS may instead be 
made from its molecular signature [5,6, 7]. 
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In terms of osteosarcoma subtypes, HGOS include primary and secondary 
conventional sub-types, telangiectatic and small cell OS [5]. Conventional HGOS represent 
90% of cases and are divided into osteoblastic/sclerosing (76-96%), chondroblastic (10-13%) 
and fibroblastic (10%) OS, based on the type of matrix produced by the tumor cells. Other 
subtypes include osteoblastoma-like (which are rich in giant cells), epithelioid, clear cell, and 
chondroblastoma-like OS. Secondary OS often develop in Paget’s disease or in irradiated 
areas and occasionally after bone infarction or in the presence of benign tumors such as 
fibrous dysplasia. They have never been reported in cases of ossifying fibroma. Conventional 
HGOS have a complex genomic profile, with different molecular alterations of MDM2 and 
CDK4 reported than those observed in LGOS or differentiated/dedifferentiated OS [8].  
MOS may morphologically overlap with benign tumors such as fibrous dysplasia and 
ossifying fibromas [1]. Fibrous dysplasia tumors exhibit immature irregularly-shaped 
curvilinear trabeculae of woven bone associated with bland fibroblastic cells exhibiting rare 
mitoses. The juvenile type of ossifying fibroma (JOF) may resemble osteoblastoma [9]. JOF 
contain fusiform and giant plurinucleated cells surrounded by immature peripheral osseous 
trabecular structures that are then surrounded by osteoblastic cells. Activating mutations in the 
GNAS (guanine nucleotide-binding protein/alpha subunit) gene occur in up to 50% of fibrous 
dysplasias [10;11] and occasionally in LGOS [12] but have not been identified in ossifying 
fibromas [11]. The amplification of chromosome 12 which harbors the MDM2 and RASAL1
(RAS protein activator like-1; telomeric to MDM2 on chromosome 12) genes has also been 
recently identified as a molecular diagnostic marker for ossifying fibromas (mostly of 
juvenile-type) and is associated with aggressive tumors [13]. Alterations to the RASAL1 and 
MDM2 genes have not been reported in OS, however in some fibrous dysplasias and ossifying 
fibromas MDM2 amplification has been reported without an accompanying overexpression of 
the MDM2 protein [6].  
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Due to the significant overlap in the morphological and molecular presentation of 
benign and malignant mandibular tumors, a more comprehensive molecular characterization 
is required and should have a significant prognostic and therapeutic impact. In this study we 
have characterized the spectrum of MOS using immunohistochemistry and molecular 
techniques (quantitative polymerase chain reaction: qPCR, sequencing) and compared these 
with benign fibro-osseous lesions to investigate whether MOS that are histologically different 
exhibit distinct molecular features.  
1.2 MATERIALS AND METHODS 
1.2.1 Patient and tumor characteristics 
Institutional and national ethics committees approved this retrospective study. Patient 
samples were obtained after authorization by the French Ministry of Higher Education and 
Research (declaration DC 2009-989; DC-2011-1388; transfer agreement AC-2008-820; AC-
2011-130). The institution that granted permission was the "Comité de Protection des 
Personnes Sud Ouest et Outre Mer I", Agence Régionale de Santé Midi-Pyrénées, Toulouse. 
Clinical and biological annotations were consistent with the CNIL (Comité National 
Informatique et Libertés) guidelines. All patient records and information were anonymized 
and de-identified prior to analysis. Samples were stored in the “CRB cancer des Hôpitaux de 
Toulouse; BB-0033-00014” collection.  
Forty-nine MOS and 25 benign fibro-osseous tumor samples were collected from 
patients treated between 1997 and 2013. Clinical data (age, gender) and histological 
characteristics (grade, histological subtype) are reported in Table 1 (see Results section 1.3.1).  
Paraffin-embedded tissue samples were collected from different institutions belonging 
to the Groupe Sarcome Français - Groupe d’Etude des Tumeurs Osseuses (French Sarcoma 
Group - Bone Tumor Study Group; GSF-GETO), the Rare Cancer Network (RCN) and the 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
10 
 
Reseau d’Expertise Français des Cancers ORL Rares (French Network of Expertise on Rare 
Ear, Nose and Throat Cancers; REFCOR). Hematoxylin-eosin-stained histology slices were 
blindly examined by two pathologists (AGB, MG) from the French Group of Bone Tumor 
Pathologists (GFPO) who further selected blocks to be used for tissue microarrays (TMAs). 
TMAs (triplicate sampling) were performed as recommended by Kononen et al. [14] . Since 
fixation and decalcification protocols have altered over time (some samples were fixed in 
formol and some in picric acid), wherever possible tumor samples from different tumor 
blocks for a given patient were used to compensate for any potential differences due to 
fixation and decalcification methods. 
The 49 tumors were reviewed by the GFPO and reclassified into three subtypes 
(chondroblastic/osteoblastic/fibroblastic) based on the prominent component and according to 
the WHO 2013 classification. Fibroblastic (FB) osteosarcomas were subdivided based on the 
presence or absence of giant cells, with “FB*” denoting suspected HGOS with part LGOS 
(differentiated/dedifferentiated OS) and “FB giant cells” denoting suspected ossifying-
fibroma-like OS (see Tables 1 and 2, Results sections 1.3.1 and 1.3.2 respectively). The 25 
maxillary benign fibro-osseous tumors were collected from the University Hospital of 
Toulouse and included 10 fibrous dysplasias and 15 ossifying fibromas. 
1.2.2 Immunohistochemistry
The Ki67 proliferation index and MDM2 immunostainings were performed. Vessels 
were stained to detect the presence of CD34. Preparations were dried for 1 hour at 58°C, then 
overnight at 37°C. Sections were deparaffinized with toluene and rehydrated in ethanol. They 
were then pretreated with the high pH target retrieval solution (DAKO, EnVision Flex, 
Denmark), and a heat-based antigen retrieval method was used before incubation. 
Endogenous peroxidase was blocked using a 3% H2O2 incubation for 5 minutes. The primary 
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CD34 antibody was used at a 1:200 dilution (Beckman Coulter, CA, USA; clone QBEnd 10) 
and the primary Ki67 antibody was used at a 1:150 dilution (DAKO, Denmark; clone MIB-1).
Sections were incubated for 20 minutes at room temperature. For MDM2 immunostaining, 4 
μm-thick paraffin sections were mounted onto glass slides (Superfrost, DAKO, Trappes, 
France). Preparations were dried for 1 hour at 58°C, and overnight at 37°C. Sections were 
then deparaffinized with toluene and rehydrated in ethanol. They were pretreated with EDTA 
(MS-Unmasker-Diapath, Martinengo, Italy) and then a heat-based antigen retrieval method 
was used before incubation. Endogenous peroxidase was blocked using a 3% H2O2 incubation 
for 5 minutes. The primary MDM2 antibody was used at a 1:25 dilution (Zymed Laboratories, 
CA, USA; clone IF2) and sections were incubated for 1 hour at 22°C. Staining was performed 
with the Envision kit (DAKO, Carpinteria, CA, USA); sections were revealed by incubation 
in a diaminobenzidine solution for 7 minutes then staining with hematoxylin for 16 seconds.
MDM2 immunostaining was performed for each case of ossifying fibroma, fibrous dysplasia 
and for all subtypes of MOS. Only well-defined nuclear reactivity was considered positive. 
Immunoreactivity was considered positive when 1-100% of cells were stained, irrespective of 
staining intensity.  
1.2.3 Molecular studies 
1.2.3.1. DNA Extraction  
Genomic DNA was extracted using the QIAamp DNA FFPE Extraction kit (Qiagen, 
Courtaboeuf, France) from 10 mm sections cut from tissue blocks of each of the 49 cases. 
Thick sections of FFPE tissue were dewaxed by extraction in 100% xylene and washed with 
100% ethanol. Samples were then air-dried before DNA extraction. Extracted DNA was 
quantified using a spectro-photometer (Cary100Scan Varian, Agilent, Massy, France).  
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1.2.3.2 qPCR 
qPCR was performed using a Light Cycler 480 (Roche, Boulogne, France) with 50 ng DNA 
using the Sybr Green I Master kit (Roche). The ALB gene was used as a reference. Primer
sequences are given in Table 1. PCR was carried out as follows: following 5 minutes at 95°C, 
45 amplification cycles were run, each consisting of 10 seconds at 95°C, 10 seconds at 60°C 
and 10 seconds at 72°C. The relative amounts of MDM2 and RASAL1 were established as a 
ratio of the reference gene (ALB) using Light Cycler Relative Quantification software  
1.2.3.3 GNAS mutations  
GNAS mutations in patients were determined as previously described [11]. All PCR 
and sequencing reactions were run in duplicate. Briefly, exon 8 of GNAS was screened by 
high resolution melt (HRM) using High Melting Master Kit (Roche). The GNAS HRM 
primers were: forward 5’-TCCATTGACCTCAATTTTGTTTCAG-3’ and reverse 5’-
AAGTTGACTTTGTCCACCTGGAACT-3’ (Invitrogen, ThermoFisher Scientific, USA). 
Alternatively, GNAS mutations (exon 8: p.R201C and p.R201H, exon 9: p.Q227L) were 
genotyped by allele-specific PCR using a Light Cycler 480 SYBR Green I Master Kit 
(Roche), as previously described [11]. HRM and allele-specific PCR positive findings were 
further sequenced using bidirectional Sanger sequencing. 
1.3 RESULTS 
1.3.1 Clinical and pathological findings 
Of the 49 patients treated for MOS in this series, 28 were male and 21 were female 
(Table 1). Eight occurred in irradiated areas. All were HGOS, with 18 chondroblastic, 16 
osteoblastic and 15 fibroblastic OS. Eight of the fibroblastic cases included a high- and a low-
grade component suggestive of a possible dedifferentiated osteosarcoma (shown by FB* in 
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Table 1). In general, the low-grade component resembled either a desmoid tumor, with areas 
of moderately atypical fibroblastic cells in a fibrous stroma, or areas of well-differentiated 
osteogenesis associated with moderately atypical fibroblastic cells (Figure 1). Seven other 
fibroblastic cases that were rich in giant cells (see Table 1) had fibroblastic areas resembling 
JOF (areas of immature osteogenesis interspersed with fibroblastic areas and giant cells) 
(Figure 2). 
Due to the low number of patients in each category, no significant prognostic 
correlations could be made. 
1.3.2 MDM2 immunohistochemistry 
Of the 49 cases, 36 were suitable for immunohistochemistry analysis. Thirteen cases were 
excluded since control CD34 and Ki67 immunostainings were negative and these samples 
were assumed to have inadequate tissue quality due to decalcification. All of the 25 benign 
fibro-osseous tumor samples had positive CD34 and Ki67 staining and all were negative for 
MDM2 overexpression. Three MOS cases showed nuclear MDM2 immunostaining (Figure 3 
and Table 3); these were all of fibroblastic subtype and differentiated/dedifferentiated OS was 
suspected. All other subtypes, including the seven giant cell fibroblastic OS cases, were also 
negative for MDM2 staining. 
1.3.3 Molecular findings 
Fifteen cases were suitable for molecular analysis based on the quantity and/or quality 
of their extracted DNA (Table 2). 
1.3.3.1 Amplification of MDM2 and RASAL1 
Five cases showed MDM2 amplification by qPCR. These were fibroblastic 
osteosarcomas, and included two cases in which differentiated/dedifferentiated osteosarcoma 
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was observed microscopically. These two cases had also shown MDM2 overexpression by 
IHC analysis. Unfortunately qPCR could not be used in the third case exhibiting 
overexpressed MDM2 due to insufficient DNA quality. The other three cases showing MDM2
amplification by qPCR also contained an amplification of RASAL1, but did not have MDM2 
overexpression. These three cases were of the giant cell-rich fibroblastic subtype, with areas 
mimicking JOF. There were four other giant cell-rich fibroblastic OS, all of which had no 
MDM2 overexpression. One was negative for MDM2 and RASAL1 amplification but 
molecular analyses could not be performed on the other three due to poor DNA quality. 
1.3.3.2 GNAS mutations 
Due to insufficient quality or quantity of the DNA extracted, 35 samples had 
inconclusive results regardless of the techniques used. However, GNAS mutations were not 
detected in the remaining 14 cases. 
1.4 DISCUSSION
 This study is the largest to date to compare high-grade MOS samples. We have shown 
that different subtypes of high-grade MOS (graded according to the WHO 2013 classification) 
can be characterized based on their morphology, immunohistochemistry and molecular 
biology. This has important implications in terms of the prognosis and understanding of the 
pathobiology of the MOS spectrum. MOS are usually treated based on their grade [15, 16],
with recent data suggesting that complete resection with neoadjuvant chemotherapy gives the 
best outcome for HGOS while LGOS are better treated with surgery alone [2]. However, our 
results suggest that this strategy overlooks potentially different behaviors within a given 
HGOS subtype.  
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According to the molecular criteria of the WHO 2013 classification, LGOS and its 
dedifferentiated contingent (HGOS with part LGOS) are characterized by the amplification of 
MDM2, whereas conventional HGOS are thought to harbor a complex genomic profile with 
no distinct molecular signature. 
Recent studies have suggested that benign fibro-osseous tumors of the jaw exhibit 
specific molecular characteristics. JOF can harbor a RASAL1 and MDM2 amplification that is 
associated with a greater clinical aggressiveness [13]. In addition, in both its monostotic or 
polyostotic presentations, or when associated with McCune Albright syndrome, fibrous 
dysplasia is characterized by somatic mutations of GNAS located on chromosome 20q13.3. 
[11,17]. However, GNAS mutations have not been reported in other benign fibro-osseous 
lesions. In LGOS, the presence of GNAS mutations is controversial [11,12,18], but a recent 
study of 31 cases of LGOS (confirmed through molecular analysis), led by the French Group 
of Bone Tumor pathologists (GFPO), did not find any GNAS mutations in either LGOS or its 
dedifferentiated contingent, supporting the specificity of GNAS mutations to fibrous dysplasia 
[18]. In accordance with this [11, 18], none of the 14 OS cases in our cohort with adequate 
DNA quality contained GNAS mutations.   
Despite the heterogeneous fixation and decalcification methods used and the 
limitations of using tissue microarrays rather than slides, we were able to assess the diagnostic 
value of MDM2 overexpression, MDM2 gene amplification, GNAS mutations and 
RASAL1/MDM2 amplifications. MDM2 overexpression can also be confirmed by FISH or 
CGH array analysis [10,11], however qPCR is usually used for decalcified tissues since FISH 
is not usually interpretable. 
Our results show that molecular biology, alongside immunochemistry and 
morphological examination, can distinguish between the three subtypes of HGOS.
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Two HGOS exhibited MDM2 overexpression by immunohistochemistry analysis and 
MDM2 amplification by qPCR. These two OS exhibited morphologically-distinct areas of 
low-grade and high-grade fibroblastic OS. The third case, which was morphologically similar 
to the other two, overexpressed MDM2 but qPCR could not be performed because the tissues 
were damaged due to fixation and/or decalcification. Thus, based on the molecular pathology 
guidelines of the WHO classification, these three OS cases were reclassified as 
differentiated/dedifferentiated OS (HGOS with part LGOS), which have a better prognosis 
than conventional HGOS with its complex genomic profile [14].  
Three other OS in our series contained a co-amplification of RASAL1/MDM2, without 
an accompanying MDM2 overexpression. Microscopic examination showed areas of giant 
cells or areas resembling JOF. Chromosome 12 amplifications of both the RASAL1 and 
MDM2 genes were recently identified as being potentially useful for the molecular diagnosis 
of ossifying fibromas and as a marker of clinical aggressiveness [13].  The observation of 
such amplification in high-grade giant cell (fibroblastic) OS harboring morphological 
resemblance with JOF questions the possibility that there is a continuum between the two 
entities. Malignant transformation of ossifying fibromas into OS has never been reported. Our 
results show that the two entities share molecular abnormalities and support the hypothesis of 
a RASAL1/MDM2 co-amplification as well as a poor prognostic value / transformation risk 
when such molecular abnormality is found in ossifying fibromas. A RASAL1/MDM2 co-
amplification was absent in one giant cell-rich case, and three other giant cell-rich OS could 
not be analyzed because of tissue damage due to fixation and/or decalcification. Such 
technical issues were unavoidable owing to the rarity of disease, bone involvement and 
retrospective multicenter nature of the study.  
This large study shows that high-grade MOS can be divided into subtypes of distinct 
pathogenesis (Table 4). This could potentially improve prognosis and guide therapies. In 
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future, the use of non-decalcified tissues or other extraction procedures should improve DNA
integrity and permit the use of techniques such as CGH arrays or NGS. This will further 
develop these unique results and will ultimately improve our understanding of the etiological 
molecular pathways involved in MOS. 
1.5 CONCLUSION 
This large study is the first description of a comprehensive overview of MOS, 
assessed by MDM2, RASAL1 and GNAS status. Two unique conclusions can be made from 
our study: 1) Some high-grade MOS may result from the transformation of LGOS (defined by 
an overexpression and amplification of MDM2), as has been reported for long bone OS; 2) It 
is possible that JOF could evolve into HGOS characterized by MDM2 and RASAL1 co-
amplification. Thus, a new entity, OS with “JOF-like genotype”, could be established.  In 
addition, the presence of a RASAL1 amplification in ossifying fibromas may constitute an 
early molecular signature that requires closer follow-up and more aggressive management.  
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FIGURE LEGENDS 
Figure 1. A. Histological appearance of dedifferentiated osteosarcoma with fibrous dysplasia-
like area (right) and atypical fibroblastic cells (left) (X 2.5). HE, hematoxylin eosin. B. High-
grade fibroblastic osteosarcoma area (X 200) (HE). 
Figure 2: Histological appearance of fibroblastic osteosarcoma rich in giant cells.  
A. Osteoblastoma-like pattern with immature osteogenesis, fibroblastic cells and osteoclastic 
cells (X 2.5). B. Abnormal mitosis and atypical fibroblastic or osteoblastic cells producing 
tumoral osteoid matrix (X 200). C. Histological appearance of juvenile trabecular variant of 
ossifying fibroma with immature osteogenesis and giant cells. 
Figure 3. A. MDM2 nuclear immunostaining in a dedifferentiated osteosarcoma. B.
Fibroblastic high-grade osteosarcoma. 
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Patient Histology Grade Sex Age Response to treatment
1 CB HG M 61 GR
2 CB HG M 34 PR
3 CB HG F 29 PR
4 CB HG M 36 None
5 CB HG F 56 PR
6 CB HG M 64 PR
7 CB HG M 15 PR
8 CB HG F 25 PR
9 CB HG M 32 -
10 CB HG M 29 None
11 CB HG M 65 -
12 CB HG F 44 PR
13 CB HG M 19 PR
14 CB HG M 19 PR
15 CB HG M 77 None
16 CB HG F 33 None
17 CB HG F 35 -
18 CB HG M 31 GR
19 CB HG M 35 PR
20 FB giant cells HG F 80 None
21 FB giant cells HG - - -
22 FB giant cells HG M 55 PR
23 FB giant cells HG - - -
24 FB giant cells HG F 80 -
25 FB giant cells HG M 31 None
26 FB giant cells HG F 68 PR
27 FB IIr HG F 18 PR
28 FB* HG F 21 None
29 FB* HG M 21 PR
30 FB* HG F 31 PR
31 FB* HG F 61 None
32 FB* HG M 49 PR
33 FB* HG M 26 PR
34 FB* HG F 13 PR
35 FB* HG M 77 None
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36 OB HG F 32 PR
37 OB HG F 45 -
38 OB HG M 46 GR
39 OB HG F 49 None
40 OB HG M 25 GR
41 OB HG M 50 PR
42 OB HG F 68 PR
43 OB IIr HG F 64 -
44 OB IIr HG M 25 -
45 OB IIr HG M 47 -
46 OB IIr HG M 34 -
47 OB IIr HG M 60 GR
48 OB IIr HG F 65 PR
49 OB IIr HG F 36 -
Table 1. Clinical and pathological findings in patients with mandibular osteosarcoma.
Abbreviations: CB, chondroblastic; FB, fibroblastic; OB, osteoblastic; IIr, secondary 
osteosarcoma (post-radiation); FB* (suspected differentiated/dedifferentiated osteosarcoma);
FB giant cells (suspected ossifying-fibroma-like OS); HG, high-grade; M, male; F, female; 
GR, good responder; PR, poor responder; -, no information. 
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Patient Histology IHCMDM2
qPCR 
MDM2
qPCR 
RASAL1 GNAS CD34 KI67
1 CB - - - - - +
4 CB - NA NA NA + -
6 CB - NA NA NA + -
7 CB - NA NA NA + -
9 CB - - - - + -
14 CB - NA NA NA - +
15 CB - NA NA NA - +
17 CB - NA NA NA - +
18 CB - NA NA NA + +
20 FB giant cells - + + - + +
21 FB giant cells - NA NA NA + +
22 FB giant cells - + + NA - +
23 FB giant cells - - - - - +
24 FB giant cells - + + - + +
25 FB giant cells - NA NA NA + -
27 FB IIr - NA NA NA + +
28 FB* - - - - + +
29 FB* - NA NA NA + -
30 FB* - - - - + +
31 FB* + + - - - +
32 FB* + + - - - +
33 FB* - - - - - +
34 FB* + NA NA NA - +
35 FB* - NA NA NA + -
36 OB - NA NA NA + -
37 OB - NA NA NA - +
38 OB - - - - + +
39 OB - NA NA NA + +
40 OB - NA NA NA + +
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41 OB - NA NA NA - +
42 OB - - - - + +
43 OB IIr - NA NA NA - +
44 OB IIr - NA NA NA + +
45 OB IIr - NA NA NA + +
47 OB IIr - - - - + -
48 OB IIr - NA NA NA + +
 
Table 2. Immunohistochemistry and molecular results in mandibular osteosarcomas 
Abbreviations: CB, chondroblastic; FB, fibroblastic; OB, osteoblastic; IIr, secondary 
osteosarcoma (post-radiation); FB* (suspected differentiated/dedifferentiated osteosarcoma); 
FB giant cells (suspected ossifying-fibroma-like OS); IHC, immunohistochemistry; NA, not 
assessable; -, negative; +, positive. 
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Gene (locus) Sequence
MDM2-F (12q13-15)
MDM2-R
RASAL1-F (12q23-24)
RASAL1-R
ALBUMIN-F (4q13.3)
ALBUMIN-R
5’-CCGGAT GATCGCAGGTG-3’
5’-AAAAGCTG AGTCAACCTGCCC-3’
5’-TGGATTTCTCTTCTTGCGATTCT-3’
5’-TGTTGGTCCCGAAGGTCAAA-3’
5’-TGAAACATACGTTCCCAAAGAGTTT-3’
5’-CTCTCCTTCTCAGAAAGTGTGCATAT-3’
Table 3. Sequences of primers used for quantitative polymerase chain reaction. 
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IHC
MDM2
qPCR MDM2
amplification
qPCR RSAL1
amplification
GNAS
mutation Diagnosis
+ + - -
Differentiated/ dedifferentiated 
osteosarcoma
- + + -
Fibroblastic high-grade 
osteosarcoma with giant cells
- + + - Ossifying fibroma
- +/- +/- + Fibrous dysplasia
Table 4. Summary of IHC and molecular data. 
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